Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Gotlib

Showing results (101-110 of 210) with videos related to

Pageof 21
Sort By:
The Journal of Allergy and Clinical Immunology|May 22, 2020
Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosisKarin Hartmann, Jason Gotlib, Cem Akin, et al.
Blood|November 4, 2006
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaJeffrey E Lancet, Ivana Gojo, Jason Gotlib, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 7, 2020
Real-World Outcomes of Ruxolitinib Treatment for Polycythemia VeraAlexander Coltoff, Ruben Mesa, Jason Gotlib, et al.
The World Allergy Organization Journal|March 23, 2026
Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosisThanai Pongdee, Mariana Castells, Cem Akin, et al.
Cancer Genetics|October 14, 2017
A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophiliaAlfred Chung, Yanli Hou, Robert S Ohgami, et al.
Leukemia Research|February 22, 2018
Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasmsTariq I Mughal, Jason Gotlib, Ruben Mesa, et al.
Blood|December 28, 2007
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemiaMitch Raponi, Jeffrey E Lancet, Hongtao Fan, et al.
JAMA Oncology|March 10, 2018
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical TrialJohn Mascarenhas, Ronald Hoffman, Moshe Talpaz, et al.
Blood Advances|May 31, 2022
Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosisAndreas Reiter, Juliana Schwaab, Daniel J DeAngelo, et al.
Blood|June 28, 2022
Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNsJonas S Jutzi, Anna E Marneth, Michele Ciboddo, et al.
Pageof 21

Showing results (101-110 of 210) with videos related to

Sort By:
Pageof 21
The Journal of Allergy and Clinical Immunology|May 22, 2020
Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosisKarin Hartmann, Jason Gotlib, Cem Akin, et al.
Blood|November 4, 2006
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaJeffrey E Lancet, Ivana Gojo, Jason Gotlib, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 7, 2020
Real-World Outcomes of Ruxolitinib Treatment for Polycythemia VeraAlexander Coltoff, Ruben Mesa, Jason Gotlib, et al.
The World Allergy Organization Journal|March 23, 2026
Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosisThanai Pongdee, Mariana Castells, Cem Akin, et al.
Cancer Genetics|October 14, 2017
A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophiliaAlfred Chung, Yanli Hou, Robert S Ohgami, et al.
Leukemia Research|February 22, 2018
Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasmsTariq I Mughal, Jason Gotlib, Ruben Mesa, et al.
Blood|December 28, 2007
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemiaMitch Raponi, Jeffrey E Lancet, Hongtao Fan, et al.
JAMA Oncology|March 10, 2018
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical TrialJohn Mascarenhas, Ronald Hoffman, Moshe Talpaz, et al.
Blood Advances|May 31, 2022
Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosisAndreas Reiter, Juliana Schwaab, Daniel J DeAngelo, et al.
Blood|June 28, 2022
Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNsJonas S Jutzi, Anna E Marneth, Michele Ciboddo, et al.
Pageof 21